Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Licogliflozin dose-finding in T2DM with Heart Failure
NCT03152552Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 2, randomised, double-blind trial of licogliflozin in type 2 diabetes mellitus (T2DM) and heart failure (HF) (5 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in N-terminal Pro B-type Natriuretic Peptide at 12 weeks. Started Jul 2017; status: terminated.
02
Drugs
licogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)
Beyond the preview
Go deeper on NCT03152552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03152552.